

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10785230	
	Filing Date		2004-02-26	
	First Named Inventor	Tadamitsu Kishimoto		
	Art Unit	1642		
	Examiner Name	Laura B. Goddard		
	Attorney Docket Number	046124-5042-01		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0666868	EP	B2	1995-08-16	Genentech, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10785230
Filing Date	2004-02-26
First Named Inventor	Tadamitsu Kishimoto
Art Unit	1642
Examiner Name	Laura B. Goddard
Attorney Docket Number	046124-5042-01

1	Aluti et al. (1997), The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood, J. Exp Med. 185:111-20.	<input type="checkbox"/>
2	Amara et al. (1997), HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication, J. Exp Med. 186:139-46.	<input type="checkbox"/>
3	Asahara et al. (1997), Isolation of putative progenitor endothelial cells for angiogenesis, Science 275:964-7.	<input type="checkbox"/>
4	Bouck et al. (1996), How tumors become angiogenic, Adv Cancer Res. 69:135-74.	<input type="checkbox"/>
5	Carmeliet (1996), Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature 380:435-9.	<input type="checkbox"/>
6	Carmeliet P, Jain RK. (2000), Angiogenesis in cancer and other diseases, Nature 407:249-57.	<input type="checkbox"/>
7	Chen et al. (2003), Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in Vitro, Cancer Res. 63:4801-4	<input type="checkbox"/>
8	Ferrara et al. (1996), Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature 380: 439-42.	<input type="checkbox"/>
9	Folkman, J. (1971), Tumor angiogenesis: Therapeutic Implications. New Engl. J. Med. 285:1182-6.	<input type="checkbox"/>
10	Folkman, J. (1990), What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82:4-6.	<input type="checkbox"/>
11	Haeberlin et al. (1993), In vitro evaluation of dexamethasone-beta-D-glucuronide for colon-specific drug delivery, Pharm Res. 10:1553-62.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10785230
Filing Date	2004-02-26
First Named Inventor	Tadamitsu Kishimoto
Art Unit	1642
Examiner Name	Laura B. Goddard
Attorney Docket Number	046124-5042-01

12	Leon, L. (2005), Invited review: The use of gene knockout mice in thermoregulation studies, J. Thermal Biol. 30:273-88.	<input type="checkbox"/>
13	Ma et al. (1998), Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice, Proc Natl Acad Sci USA 95:9448-53.	<input type="checkbox"/>
14	Müller, U. (1999), Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. Mechanism of Development 82:3-21.	<input type="checkbox"/>
15	Shalaby et al. (1995), Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice, Nature 376: 62-6.	<input type="checkbox"/>
16	Smith et al. (2004), CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res. 64: 8604-12.	<input type="checkbox"/>
17	Spano et al. (2004), Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome, Ann Oncol. 15:613-7.	<input type="checkbox"/>
18	Weis et al. (2008), Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK, J. Cell Biol. 181:43-50.	<input type="checkbox"/>
19	Zou et al. (1998), Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development, Nature 393:524-5.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.